Overview
NICE is unable to make a recommendation on imlunestrant (Inluriyo) for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy in adults. This is because the company did not provide an evidence submission.
Last reviewed: 18 June 2026
Next review: We will review this decision if the company decides to make a submission.